EW Earnings & Financial Statements
Edwards Lifesciences Corporation
$86.45
+$1.18(+1.38%)
40
Overall
55
Value
20
Tech
47
Quality
Market Cap
$49.83B
Volume
4.04M
52W Range
$72.30 - $96.29
Target Price
$101.59
EW earnings and financial statements: Edwards Lifesciences Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
EW Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $5.38B | $5.23B |
| Cost of revenue | $1.33B | $1.12B | $978.40M | $1.08B | $1.25B |
| Operating income | $1.26B | $1.38B | $1.31B | $1.75B | $1.69B |
| EBITDA | $1.48B | $1.75B | $1.56B | $1.95B | $1.86B |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| EPS (diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B |
| Shareholders’ equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B |
| Cash and equivalents | $2.94B | $3.05B | $1.13B | $769.00M | $862.80M |
| Long-term debt | $680.90M | $676.60M | $662.20M | $665.80M | $664.80M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.60B | $542.30M | $895.80M | $1.22B | $1.73B |
| Capital expenditure | -$260.20M | -$282.40M | -$266.30M | -$264.80M | -$329.80M |
| Free cash flow | $1.33B | $259.90M | $629.50M | $953.40M | $1.40B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EW | $86.45 | +1.4% | 4.04M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Edwards Lifesciences Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW